Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Solid Biosciences heads into its November earnings with short sellers trimming positions, analysts uniformly bullish at targets far above the current price, and three activist investors carrying 13D filings on the register.
Short interest has fallen meaningfully over the past month. It peaked near 16.9 million shares in mid-September and has eased to roughly 15 million shares by October 8, a decline of around 8% over 30 days. At 19.2% of the free float, the position is still substantial, but the direction of travel is clearly lower. Days to cover stand at 7.7 on the most recent FINRA fortnightly count, so unwinding remains a slow process. The borrow market offers no particular squeeze catalyst here: cost to borrow is just 0.51%, and availability is running at more than 500% of short interest, meaning there are roughly five shares available to lend for every one currently borrowed. That is a loose lending market, and short sellers face no mechanical pressure from the borrow side. The ORTEX short score sits at 69.3, elevated but steady, consistent with a stock where bearish positioning is real but not extreme.
Options positioning reinforces the bullish lean. The put/call ratio has dropped to 0.07, well below its 20-day average of 0.11. Call volume is running at roughly fourteen times the put volume, an unusually lopsided ratio that places SLDB near the low end of its 52-week PCR range. That is not a defensive setup: options traders are positioning for upside, not hedging against downside. The contrast with the short book is notable. Roughly a fifth of the float is still sold short, yet the options market is pricing in very little near-term downside risk.
The Street is equally one-sided. All eight analysts covering the stock carry buy-equivalent ratings. The most recent move came from RBC Capital, which initiated coverage on September 16 at Outperform with an $18 target. That follows Cantor Fitzgerald raising its target to $26 from $16 in late August, and Truist Securities lifting to $20 from $16 days earlier. The average target now sits well above $18, against a share price of $6.87. The bull case rests on SGT-003, the company's Duchenne muscular dystrophy program: 53 patients dosed with no reported drug-induced liver injury, and biomarker signals on microdystrophin, nNOS and cardiac endpoints that the bulls argue are meaningfully differentiated from rivals. A late fourth-quarter FDA meeting and a year-end or early-2027 functional readout are the key de-risking events the Street is waiting on. The bear case points to sector-wide AAV safety history, the restrictions placed on ELEVIDYS following severe acute liver failure cases in 2025, and the reality that Solid is burning cash toward a program that has not yet reached approval. The price-to-book multiple has compressed sharply, falling more than 1.4 points over 30 days to 3.9x, reflecting the 31% one-month price decline. EPS momentum factor scores rank in the bottom quartile of the universe, and the short score factor rank sits at just 12 out of 100, flagging the stock as one of the more heavily shorted names in its peer group.
The ownership picture adds another layer to the story. Three investors hold Schedule 13D filings on SLDB, meaning they have disclosed activist intent: RA Capital Management at 11.9% of shares (up from 9.9%), BCLS II Investco at 8.8% (up from 7.8%), and Perceptive Advisors at 11.2% (slightly reduced from 12.9%). That concentration of activist capital, combined with specialist biotech funds Bain Capital Life Sciences at 9.1% and Artal Group at 7.2%, means the top five holders control more than 47% of shares. BlackRock and FMR LLC (Fidelity) have both added to their positions recently, with BlackRock adding roughly 2 million shares and Fidelity adding 3.3 million as of late September. State Street added 3 million shares in the same period. Insider activity is less informative: the only SEC-reported open-market transactions in the 90-day window are a routine director option exercise, and the February cluster of executive sales were all made under pre-arranged 10b5-1 plans, which limits what can be read into them.
Earnings are due November 6. Recent history shows the stock has fallen on the day in three of the last four prints, with losses ranging from 1.7% to 5.4%, though it has recovered ground over the subsequent five days in each case. The late fourth-quarter FDA meeting and functional data readout are the events that will matter most to positioning: how those catalysts land will determine whether the gap between a $6.87 stock and an $18-plus analyst consensus begins to close.
See the live data behind this article on ORTEX.
Open SLDB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
